Literature DB >> 27086790

Imidazo[1,2-a]pyridines: Promising Drug Candidate for Antitumor Therapy.

Richa Goel, Vijay Luxami, Kamaldeep Paul1.   

Abstract

Imidazo[1,2-a]pyridine has been shown to be an important biologically active moiety. This review is a compilation of the scattered output of results of the anticancer activities of the imidazo[1,2-a]pyridine system since 2001, which have been classified as inhibition of CDK, VEGFR, PI3K, EGFR, RGGT etc. along with inhibition against different tumor cell lines. Various imidazo[1,2-a]pyridine based analogues have been used as lead molecules and are now under human clinical trials. This review will help the wider scientific community in the area of drug discovery of imidazo[1,2-a]pyridines as novel anticancer agents.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27086790     DOI: 10.2174/1568026616666160414122644

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  10 in total

1.  Synthesis of 4-alkylaminoimidazo[1,2-a]pyridines linked to carbamate moiety as potent α-glucosidase inhibitors.

Authors:  Mina Saeedi; Maryam Raeisi-Nafchi; Sepideh Sobhani; Seyedeh Sara Mirfazli; Mahsa Zardkanlou; Somayeh Mojtabavi; Mohammad Ali Faramarzi; Tahmineh Akbarzadeh
Journal:  Mol Divers       Date:  2020-10-12       Impact factor: 2.943

2.  A new cross-conjugated mesomeric betaine.

Authors:  Nivedita Sharma; Manjinder Kour; Raakhi Gupta; Raj K Bansal
Journal:  RSC Adv       Date:  2021-07-21       Impact factor: 4.036

3.  [Design and synthesis of imidazo-fused heterocycles derivatives and their anti-tumor activity against breast cancer in mice].

Authors:  Jin Zhou; Bohong Liao; Yinggui Deng; Xiaowen Guo; Jialan Zhao; Jie Sun; Zhibo Zhu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-08-30

4.  Synthesis and anticancer activity of bis(2-arylimidazo[1,2-a]pyridin-3-yl) selenides and diselenides: the copper-catalyzed tandem C-H selenation of 2-arylimidazo[1,2-a]pyridine with selenium.

Authors:  Mio Matsumura; Tsutomu Takahashi; Hikari Yamauchi; Shunsuke Sakuma; Yukako Hayashi; Tadashi Hyodo; Tohru Obata; Kentaro Yamaguchi; Yasuyuki Fujiwara; Shuji Yasuike
Journal:  Beilstein J Org Chem       Date:  2020-05-20       Impact factor: 2.883

5.  Crystal structure, Hirshfeld surface analysis and contact enrichment ratios of 1-(2,7-di-methyl-imidazo[1,2-a]pyridin-3-yl)-2-(1,3-di-thio-lan-2-yl-idene)ethanone monohydrate.

Authors:  Yvon Bibila Mayaya Bisseyou; Mahama Ouattara; Pénétjiligué Adama Soro; R C A Yao-Kakou; Abodou Jules Tenon
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2019-11-29

Review 6.  Recent Progress in Metal-Free Direct Synthesis of Imidazo[1,2-a]pyridines.

Authors:  Vanya Kurteva
Journal:  ACS Omega       Date:  2021-12-14

7.  Chemodivergent synthesis of N-(pyridin-2-yl)amides and 3-bromoimidazo[1,2-a]pyridines from α-bromoketones and 2-aminopyridines.

Authors:  Yanpeng Liu; Lixue Lu; Haipin Zhou; Feijie Xu; Cong Ma; Zhangjian Huang; Jinyi Xu; Shengtao Xu
Journal:  RSC Adv       Date:  2019-10-28       Impact factor: 4.036

Review 8.  Recent advances in metal catalyst- and oxidant-free electrochemical C-H bond functionalization of nitrogen-containing heterocycles.

Authors:  Ya-Nan Li; Bin Wang; Ye-Kai Huang; Jin-Song Hu; Jia-Nan Sun
Journal:  Front Chem       Date:  2022-08-19       Impact factor: 5.545

9.  Synthesis of novel alkynyl imidazopyridinyl selenides: copper-catalyzed tandem selenation of selenium with 2-arylimidazo[1,2-a]pyridines and terminal alkynes.

Authors:  Mio Matsumura; Kaho Tsukada; Kiwa Sugimoto; Yuki Murata; Shuji Yasuike
Journal:  Beilstein J Org Chem       Date:  2022-07-19       Impact factor: 2.544

Review 10.  1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship.

Authors:  Ting Liang; Xiangyang Sun; Wenhong Li; Guihua Hou; Feng Gao
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.